Epstein-Barr virus and renal transplantation.
Identifieur interne : 000852 ( Main/Exploration ); précédent : 000851; suivant : 000853Epstein-Barr virus and renal transplantation.
Auteurs : Jade Le [États-Unis] ; Christine M. Durand [États-Unis] ; Irfan Agha [États-Unis] ; Daniel C. Brennan [États-Unis]Source :
- Transplantation reviews (Orlando, Fla.) [ 1557-9816 ] ; 2017.
Descripteurs français
- KwdFr :
- Allogreffes (MeSH), Appréciation des risques (MeSH), Comorbidité (MeSH), Donneurs de tissus (MeSH), Défaillance rénale chronique (chirurgie), Défaillance rénale chronique (diagnostic), Défaillance rénale chronique (virologie), Femelle (MeSH), Herpèsvirus humain de type 4 (isolement et purification), Humains (MeSH), Immunosuppression thérapeutique (méthodes), Infections à virus Epstein-Barr (diagnostic), Infections à virus Epstein-Barr (épidémiologie), Mâle (MeSH), Pronostic (MeSH), Prévention primaire (méthodes), Rejet du greffon (virologie), Survie du greffon (MeSH), Sélection de donneurs (MeSH), Transplantation rénale (effets indésirables), Transplantation rénale (méthodes), Virémie (chirurgie), Virémie (diagnostic), Virémie (épidémiologie), Études séroépidémiologiques (MeSH).
- MESH :
- chirurgie : Défaillance rénale chronique, Virémie.
- diagnostic : Défaillance rénale chronique, Infections à virus Epstein-Barr, Virémie.
- effets indésirables : Transplantation rénale.
- isolement et purification : Herpèsvirus humain de type 4.
- méthodes : Immunosuppression thérapeutique, Prévention primaire, Transplantation rénale.
- virologie : Défaillance rénale chronique, Rejet du greffon.
- épidémiologie : Infections à virus Epstein-Barr, Virémie.
- Allogreffes, Appréciation des risques, Comorbidité, Donneurs de tissus, Femelle, Humains, Mâle, Pronostic, Survie du greffon, Sélection de donneurs, Études séroépidémiologiques.
English descriptors
- KwdEn :
- Allografts (MeSH), Comorbidity (MeSH), Donor Selection (MeSH), Epstein-Barr Virus Infections (diagnosis), Epstein-Barr Virus Infections (epidemiology), Female (MeSH), Graft Rejection (virology), Graft Survival (MeSH), Herpesvirus 4, Human (isolation & purification), Humans (MeSH), Immunosuppression (methods), Kidney Failure, Chronic (diagnosis), Kidney Failure, Chronic (surgery), Kidney Failure, Chronic (virology), Kidney Transplantation (adverse effects), Kidney Transplantation (methods), Male (MeSH), Primary Prevention (methods), Prognosis (MeSH), Risk Assessment (MeSH), Seroepidemiologic Studies (MeSH), Tissue Donors (MeSH), Viremia (diagnosis), Viremia (epidemiology), Viremia (surgery).
- MESH :
- adverse effects : Kidney Transplantation.
- diagnosis : Epstein-Barr Virus Infections, Kidney Failure, Chronic, Viremia.
- epidemiology : Epstein-Barr Virus Infections, Viremia.
- isolation & purification : Herpesvirus 4, Human.
- methods : Immunosuppression, Kidney Transplantation, Primary Prevention.
- surgery : Kidney Failure, Chronic, Viremia.
- virology : Graft Rejection, Kidney Failure, Chronic.
- Allografts, Comorbidity, Donor Selection, Female, Graft Survival, Humans, Male, Prognosis, Risk Assessment, Seroepidemiologic Studies, Tissue Donors.
Abstract
Epstein-Barr virus (EBV) is a gamma herpesvirus associated with diseases ranging from asymptomatic viremia to post-transplant malignancies in kidney transplant recipients. EBV specifically is associated with post-transplantation lymphoproliferative disorder (PTLD), in kidney transplant recipients, with increased risk in EBV seronegative patients with EBV seropositive donors on intensified immunosuppression. The diagnosis of PTLD relies on clinical suspicion plus tissue biopsy with polymerase chain reaction (PCR) testing of blood currently used for risk determination in high-risk recipients. Therapeutic strategies for PTLD include reduction of immunosuppression, chemotherapy and rituximab, and consideration of sirolimus-based immunosuppression. Antivirals such as ganciclovir are used to prevent reactivation of cytomegalovirus and other herpes viruses but are not onco-therapeutic. Radiation therapy or surgery is indicated for bulky, disseminated or recalcitrant disease. Prognosis varies depending on the type of malignancy identified and stage of disease.
DOI: 10.1016/j.trre.2016.12.001
PubMed: 28089555
Affiliations:
- États-Unis
- Maryland, Missouri (État), Texas
- Saint-Louis (Missouri)
- École de médecine (Université Washington de Saint-Louis)
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epstein-Barr virus and renal transplantation.</title><author><name sortKey="Le, Jade" sort="Le, Jade" uniqKey="Le J" first="Jade" last="Le">Jade Le</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Durand, Christine M" sort="Durand, Christine M" uniqKey="Durand C" first="Christine M" last="Durand">Christine M. Durand</name><affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins Medical Institute, 1830 East Monument Street, Room 450D, Baltimore, MD 21287, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins Medical Institute, 1830 East Monument Street, Room 450D, Baltimore, MD 21287</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Agha, Irfan" sort="Agha, Irfan" uniqKey="Agha I" first="Irfan" last="Agha">Irfan Agha</name><affiliation wicri:level="2"><nlm:affiliation>Dallas Renal Group, 3571 W. Wheatland Road, Suite 101, Dallas, TX 75237, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dallas Renal Group, 3571 W. Wheatland Road, Suite 101, Dallas, TX 75237</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name><affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, United States. Electronic address: dbrennan@wustl.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28089555</idno><idno type="pmid">28089555</idno><idno type="doi">10.1016/j.trre.2016.12.001</idno><idno type="wicri:Area/Main/Corpus">000896</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000896</idno><idno type="wicri:Area/Main/Curation">000896</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000896</idno><idno type="wicri:Area/Main/Exploration">000896</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Epstein-Barr virus and renal transplantation.</title><author><name sortKey="Le, Jade" sort="Le, Jade" uniqKey="Le J" first="Jade" last="Le">Jade Le</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Durand, Christine M" sort="Durand, Christine M" uniqKey="Durand C" first="Christine M" last="Durand">Christine M. Durand</name><affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins Medical Institute, 1830 East Monument Street, Room 450D, Baltimore, MD 21287, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins Medical Institute, 1830 East Monument Street, Room 450D, Baltimore, MD 21287</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Agha, Irfan" sort="Agha, Irfan" uniqKey="Agha I" first="Irfan" last="Agha">Irfan Agha</name><affiliation wicri:level="2"><nlm:affiliation>Dallas Renal Group, 3571 W. Wheatland Road, Suite 101, Dallas, TX 75237, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dallas Renal Group, 3571 W. Wheatland Road, Suite 101, Dallas, TX 75237</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name><affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, United States. Electronic address: dbrennan@wustl.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author></analytic><series><title level="j">Transplantation reviews (Orlando, Fla.)</title><idno type="eISSN">1557-9816</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allografts (MeSH)</term><term>Comorbidity (MeSH)</term><term>Donor Selection (MeSH)</term><term>Epstein-Barr Virus Infections (diagnosis)</term><term>Epstein-Barr Virus Infections (epidemiology)</term><term>Female (MeSH)</term><term>Graft Rejection (virology)</term><term>Graft Survival (MeSH)</term><term>Herpesvirus 4, Human (isolation & purification)</term><term>Humans (MeSH)</term><term>Immunosuppression (methods)</term><term>Kidney Failure, Chronic (diagnosis)</term><term>Kidney Failure, Chronic (surgery)</term><term>Kidney Failure, Chronic (virology)</term><term>Kidney Transplantation (adverse effects)</term><term>Kidney Transplantation (methods)</term><term>Male (MeSH)</term><term>Primary Prevention (methods)</term><term>Prognosis (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Seroepidemiologic Studies (MeSH)</term><term>Tissue Donors (MeSH)</term><term>Viremia (diagnosis)</term><term>Viremia (epidemiology)</term><term>Viremia (surgery)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allogreffes (MeSH)</term><term>Appréciation des risques (MeSH)</term><term>Comorbidité (MeSH)</term><term>Donneurs de tissus (MeSH)</term><term>Défaillance rénale chronique (chirurgie)</term><term>Défaillance rénale chronique (diagnostic)</term><term>Défaillance rénale chronique (virologie)</term><term>Femelle (MeSH)</term><term>Herpèsvirus humain de type 4 (isolement et purification)</term><term>Humains (MeSH)</term><term>Immunosuppression thérapeutique (méthodes)</term><term>Infections à virus Epstein-Barr (diagnostic)</term><term>Infections à virus Epstein-Barr (épidémiologie)</term><term>Mâle (MeSH)</term><term>Pronostic (MeSH)</term><term>Prévention primaire (méthodes)</term><term>Rejet du greffon (virologie)</term><term>Survie du greffon (MeSH)</term><term>Sélection de donneurs (MeSH)</term><term>Transplantation rénale (effets indésirables)</term><term>Transplantation rénale (méthodes)</term><term>Virémie (chirurgie)</term><term>Virémie (diagnostic)</term><term>Virémie (épidémiologie)</term><term>Études séroépidémiologiques (MeSH)</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Défaillance rénale chronique</term><term>Virémie</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Kidney Failure, Chronic</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Défaillance rénale chronique</term><term>Infections à virus Epstein-Barr</term><term>Virémie</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Herpesvirus 4, Human</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Herpèsvirus humain de type 4</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunosuppression</term><term>Kidney Transplantation</term><term>Primary Prevention</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Immunosuppression thérapeutique</term><term>Prévention primaire</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Défaillance rénale chronique</term><term>Rejet du greffon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Graft Rejection</term><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à virus Epstein-Barr</term><term>Virémie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Allografts</term><term>Comorbidity</term><term>Donor Selection</term><term>Female</term><term>Graft Survival</term><term>Humans</term><term>Male</term><term>Prognosis</term><term>Risk Assessment</term><term>Seroepidemiologic Studies</term><term>Tissue Donors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allogreffes</term><term>Appréciation des risques</term><term>Comorbidité</term><term>Donneurs de tissus</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Survie du greffon</term><term>Sélection de donneurs</term><term>Études séroépidémiologiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epstein-Barr virus (EBV) is a gamma herpesvirus associated with diseases ranging from asymptomatic viremia to post-transplant malignancies in kidney transplant recipients. EBV specifically is associated with post-transplantation lymphoproliferative disorder (PTLD), in kidney transplant recipients, with increased risk in EBV seronegative patients with EBV seropositive donors on intensified immunosuppression. The diagnosis of PTLD relies on clinical suspicion plus tissue biopsy with polymerase chain reaction (PCR) testing of blood currently used for risk determination in high-risk recipients. Therapeutic strategies for PTLD include reduction of immunosuppression, chemotherapy and rituximab, and consideration of sirolimus-based immunosuppression. Antivirals such as ganciclovir are used to prevent reactivation of cytomegalovirus and other herpes viruses but are not onco-therapeutic. Radiation therapy or surgery is indicated for bulky, disseminated or recalcitrant disease. Prognosis varies depending on the type of malignancy identified and stage of disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28089555</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-9816</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>01</Month></PubDate></JournalIssue><Title>Transplantation reviews (Orlando, Fla.)</Title><ISOAbbreviation>Transplant Rev (Orlando)</ISOAbbreviation></Journal><ArticleTitle>Epstein-Barr virus and renal transplantation.</ArticleTitle><Pagination><MedlinePgn>55-60</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0955-470X(16)30073-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trre.2016.12.001</ELocationID><Abstract><AbstractText>Epstein-Barr virus (EBV) is a gamma herpesvirus associated with diseases ranging from asymptomatic viremia to post-transplant malignancies in kidney transplant recipients. EBV specifically is associated with post-transplantation lymphoproliferative disorder (PTLD), in kidney transplant recipients, with increased risk in EBV seronegative patients with EBV seropositive donors on intensified immunosuppression. The diagnosis of PTLD relies on clinical suspicion plus tissue biopsy with polymerase chain reaction (PCR) testing of blood currently used for risk determination in high-risk recipients. Therapeutic strategies for PTLD include reduction of immunosuppression, chemotherapy and rituximab, and consideration of sirolimus-based immunosuppression. Antivirals such as ganciclovir are used to prevent reactivation of cytomegalovirus and other herpes viruses but are not onco-therapeutic. Radiation therapy or surgery is indicated for bulky, disseminated or recalcitrant disease. Prognosis varies depending on the type of malignancy identified and stage of disease.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Jade</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durand</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Johns Hopkins Medical Institute, 1830 East Monument Street, Room 450D, Baltimore, MD 21287, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agha</LastName><ForeName>Irfan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dallas Renal Group, 3571 W. Wheatland Road, Suite 101, Dallas, TX 75237, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, United States. Electronic address: dbrennan@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Rev (Orlando)</MedlineTA><NlmUniqueID>8804364</NlmUniqueID><ISSNLinking>0955-470X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046148" MajorTopicYN="N">Donor Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28089555</ArticleId><ArticleId IdType="pii">S0955-470X(16)30073-8</ArticleId><ArticleId IdType="doi">10.1016/j.trre.2016.12.001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>Missouri (État)</li><li>Texas</li></region><settlement><li>Saint-Louis (Missouri)</li></settlement><orgName><li>École de médecine (Université Washington de Saint-Louis)</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Le, Jade" sort="Le, Jade" uniqKey="Le J" first="Jade" last="Le">Jade Le</name></region><name sortKey="Agha, Irfan" sort="Agha, Irfan" uniqKey="Agha I" first="Irfan" last="Agha">Irfan Agha</name><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name><name sortKey="Durand, Christine M" sort="Durand, Christine M" uniqKey="Durand C" first="Christine M" last="Durand">Christine M. Durand</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000852 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000852 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28089555
|texte= Epstein-Barr virus and renal transplantation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28089555" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |